PMID- 17156669
OWN - NLM
STAT- MEDLINE
DCOM- 20080424
LR  - 20191210
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 86
IP  - 35
DP  - 2006 Sep 19
TI  - [Effects of infliximab and etanercept, two types of anti-tumor necrosis 
      factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in 
      patients with ankylosing spondylitis].
PG  - 2451-4
AB  - OBJECTIVE: To evaluate the effect of Infliximab and Etanercept two types of 
      anti-tumor necrosis factor-alpha (TNF-alpha) inhibitors, on the serum level of 
      matrix metalloproteinase 3 (MMP-3) in the pathogenesis of ankylosing spondylitis 
      (AS). METHOD: 47 patients with AS, 40 males and 7 females, aged 17 - 51, were 
      treated with Infliximab (5 mg/kg i.v at weeks 0, 2, and 6); and 26 patients with 
      AS were treated with Etanercept (25 mg, twice a week for 12 weeks). Clinical data 
      including Bath AS indices (BASDAI and BASFI) and sera were collected at baseline 
      and other different times. Erythrocyte sedimentation rate (ESR) and C-reactive 
      protein (CRP) were measured. Serum levels of MMP-3 were measured with MMP-3 ELISA 
      kits. RESULTS: Two, six, and ten weeks after Infliximab treatment the levels of 
      ESR, CRP, and serum MMP-3 of the AS patients were all significantly lower than 
      the baseline level (all P < 0.01), and the serum MMP-3 levels were all 
      significantly correlated with ESR (all P < 0.05). In the Etanercept group 1, 2, 
      4, 8, and 12 weeks after treatment the levels of serum MMP-3, ESR, CRP, BASDAI, 
      and BASFI were all significantly lower than the baseline levels (all P < 0.01); 
      before the treatment ESR was significantly correlated with CRP (r = 0.80, P < 
      0.01), BASDAI was significantly correlated with BASFI (r = 0.48, P < 0.05), and 
      MMP-3 was significantly correlated with ESR (r = 0.74, P < 0.01) and with CRP (r 
      = 0.72, P < 0.01); and 12 weeks after the treatment significant correlation still 
      existed between ESR and CRP (r = 0.40, P < 0.05), BASDAI and BASFI (r = 0.89, P < 
      0.01), and MMP-3 and ESR (r = 0.43, P = 0.029), however, there was no significant 
      correlation between CRP and serum level of MMP-3 (r = 0.37, P = 0.061). 
      CONCLUSION: Infliximab and Etanercept, 2 anti-TNF-alpha inhibitors, not only 
      significantly decrease the ESR and CRP, but also decrease the serum level of 
      MMP-3 of patients with AS. MMP-3 is involved in the pathogenesis and disease 
      activity of AS. MMP-3 is also a potentially useful marker of AS disease activity 
      and useful parameter to assess the effectiveness of anti-TNF-alpha inhibitor in 
      treatment of AS.
FAU - Yang, Chun-hua
AU  - Yang CH
AD  - Department of Rheumatology, General Hospital of Chinese People's Liberation Army, 
      Beijing, China. fhuang@301hospital.com.cn
FAU - Huang, Feng
AU  - Huang F
FAU - Deng, Xiao-hu
AU  - Deng XH
FAU - Zhang, Jiang-lin
AU  - Zhang JL
FAU - Zhang, Li-yun
AU  - Zhang LY
FAU - Guo, Jun-hua
AU  - Guo JH
FAU - Liang, Dong-feng
AU  - Liang DF
FAU - Wang, Li-sha
AU  - Wang LS
FAU - Zhang, Ya-mei
AU  - Zhang YM
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - B72HH48FLU (Infliximab)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antirheumatic Agents/therapeutic use
MH  - Blood Sedimentation
MH  - C-Reactive Protein/metabolism
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Infliximab
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Spondylitis, Ankylosing/*blood/*drug therapy
MH  - Tumor Necrosis Factor Inhibitors
EDAT- 2006/12/13 09:00
MHDA- 2008/04/25 09:00
CRDT- 2006/12/13 09:00
PHST- 2006/12/13 09:00 [pubmed]
PHST- 2008/04/25 09:00 [medline]
PHST- 2006/12/13 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2006 Sep 19;86(35):2451-4.